With great interest, we read Li and colleagues’ article1 in this issue of JAMA Surgery. The authors sought to compare the short-term outcomes of laparoscopic distal gastrectomy with those of open distal gastrectomy for the treatment of patients with locally advanced (cT2-4aN+M0) distal gastric cancer. In this study, an open-label, single center, phase 2 randomized clinical trial with a noninferiority design, the authors assessed outcomes at 3 years. All patients received neoadjuvant therapy of oxaliplatin and capecitabine before their operation. Li and colleagues1 reported significantly lower postoperative complication rates, less postoperative pain, and better adherence to and completion of adjuvant therapy among trial participants.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Sachs TE, Tseng JF. Laparoscopic Resection After Neoadjuvant Chemotherapy for Distal Gastric Tumors: Safe, but Is It Better? JAMA Surg. 2019;154(12):1101–1102. doi:10.1001/jamasurg.2019.3474
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: